JAZZ Q1 2018 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$445M+18.2% YoY

Gross Profit

$411M92.4% margin

Operating Income

$88M19.7% margin

Net Income

$46M10.3% margin

EPS (Diluted)

$0.75

QoQ Revenue Growth

+1.9%

Cash Flow

Operating Cash Flow

$162M

Free Cash Flow

$155M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$5.3B

Total Liabilities

$2.5B

Stockholders' Equity

$2.8B

Cash & Equivalents

$453M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$445M	$376M	+18.2%
Gross Profit	$411M	$351M	+17.0%
Operating Income	$88M	$136M	-35.5%
Net Income	$46M	$87M	-46.8%

Revenue Segments

Product And Services, Product Sales

$441M50%

Xyrem

$317M36%

Erwinaze And Erwinase

$51M6%

Defitelio

$35M4%

Vyxeos

$26M3%

Prialt

$6M1%

Other Products

$6M1%

Product And Services, Royalties And Contract Revenue

$4M0%

Geographic Segments

UNITED STATES

$406M91%

Europe

$28M6%

Other Countries

$11M2%